These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37902999)

  • 1. Clinical implication of genetic intratumor heterogeneity for targeted therapy in head and neck cancer.
    Gram SB; Alosi D; Bagger FO; Østrup O; von Buchwald C; Friborg J; Wessel I; Vogelius IR; Rohrberg K; Rasmussen JH
    Acta Oncol; 2023 Dec; 62(12):1831-1839. PubMed ID: 37902999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy.
    de Roest RH; Mes SW; Poell JB; Brink A; van de Wiel MA; Bloemena E; Thai E; Poli T; Leemans CR; Brakenhoff RH
    Clin Cancer Res; 2019 Dec; 25(23):7256-7265. PubMed ID: 31439582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.
    Nisa L; Barras D; Medová M; Aebersold DM; Medo M; Poliaková M; Koch J; Bojaxhiu B; Eliçin O; Dettmer MS; Angelino P; Giger R; Borner U; Caversaccio MD; Carey TE; Ho L; McKee TA; Delorenzi M; Zimmer Y
    Mol Cancer Res; 2018 Dec; 16(12):1912-1926. PubMed ID: 30108165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumor genetic heterogeneity and head and neck cancer relapse.
    Pierik AS; Poell JB; Brink A; Stigter-van Walsum M; de Roest RH; Poli T; Yaromin A; Lambin P; Leemans CR; Brakenhoff RH
    Radiother Oncol; 2024 Feb; 191():110087. PubMed ID: 38185257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
    Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
    J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The degree of intratumor mutational heterogeneity varies by primary tumor sub-site.
    Ledgerwood LG; Kumar D; Eterovic AK; Wick J; Chen K; Zhao H; Tazi L; Manna P; Kerley S; Joshi R; Wang L; Chiosea SI; Garnett JD; Tsue TT; Chien J; Mills GB; Grandis JR; Thomas SM
    Oncotarget; 2016 May; 7(19):27185-98. PubMed ID: 27034009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
    Hedberg ML; Goh G; Chiosea SI; Bauman JE; Freilino ML; Zeng Y; Wang L; Diergaarde BB; Gooding WE; Lui VW; Herbst RS; Lifton RP; Grandis JR
    J Clin Invest; 2016 Jan; 126(1):169-80. PubMed ID: 26619122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
    Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
    Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma.
    Mroz EA; Rocco JW
    Oral Oncol; 2013 Mar; 49(3):211-5. PubMed ID: 23079694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma.
    Rasmussen JH; Olin AB; Lelkaitis G; Hansen AE; Andersen FL; Johannesen HH; Kjaer A; Fischer BM; Specht L; Bentzen SM; von Buchwald C; Wessel I; Vogelius IR
    Eur J Radiol; 2021 Jun; 139():109668. PubMed ID: 33848777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
    Marret G; Bièche I; Dupain C; Borcoman E; du Rusquec P; Ricci F; Hescot S; Sablin MP; Tresca P; Bello D; Dubot C; Loirat D; Frelaut M; Lecerf C; Le Tourneau C; Kamal M
    JCO Precis Oncol; 2021 Nov; 5():215-226. PubMed ID: 34994597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumor heterogeneity could inform the use and type of postoperative adjuvant therapy in patients with head and neck squamous cell carcinoma.
    Mroz EA; Patel KB; Rocco JW
    Cancer; 2020 Jan; 126(9):1895-1904. PubMed ID: 32083741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and targeting therapy (Review).
    Li M; Sun D; Song N; Chen X; Zhang X; Zheng W; Yu Y; Han C
    Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Lee JH; Heo SG; Ahn BC; Hong MH; Cho BC; Lim SM; Kim HR
    Cancer Med; 2021 Oct; 10(20):7012-7020. PubMed ID: 34528763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC)--potential implications for clinical management and treatment decisions.
    Hass HG; Schmidt A; Nehls O; Kaiser S
    Oral Oncol; 2008 Jan; 44(1):78-85. PubMed ID: 17350326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer.
    Weber P; Künstner A; Hess J; Unger K; Marschner S; Idel C; Ribbat-Idel J; Baumeister P; Gires O; Walz C; Rietzler S; Valeanu L; Herkommer T; Kreutzer L; Klymenko O; Drexler G; Kirchner T; Maihöfer C; Ganswindt U; Walch A; Sterr M; Lickert H; Canis M; Rades D; Perner S; Berriel Diaz M; Herzig S; Lauber K; Wollenberg B; Busch H; Belka C; Zitzelsberger H
    Clin Cancer Res; 2022 Mar; 28(5):1038-1052. PubMed ID: 34965946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer.
    Solis RN; Silverman DA; Birkeland AC
    Curr Treat Options Oncol; 2022 Feb; 23(2):254-267. PubMed ID: 35195839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.